CA2306646A1 - Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires - Google Patents

Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires Download PDF

Info

Publication number
CA2306646A1
CA2306646A1 CA002306646A CA2306646A CA2306646A1 CA 2306646 A1 CA2306646 A1 CA 2306646A1 CA 002306646 A CA002306646 A CA 002306646A CA 2306646 A CA2306646 A CA 2306646A CA 2306646 A1 CA2306646 A1 CA 2306646A1
Authority
CA
Canada
Prior art keywords
phenyl
methylsulfonyl
inhibitor
dimethyl
furan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002306646A
Other languages
English (en)
Inventor
Melvin Winokur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9806688.9A external-priority patent/GB9806688D0/en
Application filed by Individual filed Critical Individual
Publication of CA2306646A1 publication Critical patent/CA2306646A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention propose une combinaison de médicaments contenant un inhibiteur de HMG-CoA réductase, associé à un inhibiteur de COX-2, servant à traiter, prévenir et/ou réduire les risques de développement de l'athérosclérose et d'apparition d'incidents pathologiques liés à l'athérosclérose.
CA002306646A 1997-10-22 1998-10-16 Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires Abandoned CA2306646A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6269197P 1997-10-22 1997-10-22
US60/062,691 1997-10-22
GBGB9806688.9A GB9806688D0 (en) 1998-03-27 1998-03-27 Combination therapy for reducing the risks associated with cardio-and cerebrovascular diease
GB9806688.9 1998-03-27
PCT/US1998/021901 WO1999020110A1 (fr) 1997-10-22 1998-10-16 Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires

Publications (1)

Publication Number Publication Date
CA2306646A1 true CA2306646A1 (fr) 1999-04-29

Family

ID=26313383

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002306646A Abandoned CA2306646A1 (fr) 1997-10-22 1998-10-16 Therapie d'association permettant de reduire les risques lies aux maladies cardio-vasculaires et cerebro-vasculaires

Country Status (5)

Country Link
EP (1) EP1024696A4 (fr)
JP (1) JP2001520174A (fr)
AU (1) AU753657B2 (fr)
CA (1) CA2306646A1 (fr)
WO (1) WO1999020110A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
CA2373940A1 (fr) * 1999-07-02 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Compositions medicamenteuses destinees au traitement du cancer colorectal
US6849257B2 (en) 2000-02-04 2005-02-01 Children's Hospital Research Foundation Lipid hydrolysis therapy for atherosclerosis and related diseases
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
EP1303265B1 (fr) 2000-07-20 2007-07-11 Lauras AS Utilisation d'inhibiteurs de cox-2 en tant qu'immunostimulants dans le traitement du vih ou du sida
US6534540B2 (en) 2000-10-06 2003-03-18 George Kindness Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
WO2002028270A2 (fr) * 2000-10-06 2002-04-11 Probiochem, Llc Combinaison et methode de traitement du cancer par un inhibiteur de cox-2 et un inhibiteur de 3-hydroxy-3-methylglutaryl-coenzyme-a (hmg-coa) reductase
WO2002094021A1 (fr) * 2000-10-06 2002-11-28 Probiochem, Llc Combinaison et methode de traitement par un inhibiteur de la cox-2, un inhibiteur de la hmg-coa et la cystine pour ameliorer la fonction du glutathion
DE60122939T2 (de) 2000-12-21 2007-01-11 Nitromed, Inc., Bedford Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
WO2004006919A1 (fr) * 2002-07-11 2004-01-22 Sankyo Company, Limited Composition medicale pour reduire le taux de lipides sanguins ou le taux d'homocysteine sanguine
JP4611622B2 (ja) * 2002-07-11 2011-01-12 第一三共株式会社 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
AU2005332300B2 (en) 2005-05-31 2011-07-07 Mylan Laboratories, Inc. Compositions comprising nebivolol
US20070037797A1 (en) * 2005-08-15 2007-02-15 Hellstrom Harold R Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events
JP2009514851A (ja) * 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
US8404275B2 (en) * 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
CA2853804C (fr) 2011-10-28 2021-06-01 Vitalis Llc Compositions anti-bouffee

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112639A0 (en) * 1994-03-11 1995-05-26 Bristol Myers Squibb Co A pharmaceutical composition containing pravastin
AU6274896A (en) * 1995-06-06 1996-12-24 Procyte Corporation Stable copper(i) complexes as active therapeutic substances
TR199801731T2 (xx) * 1996-03-05 1999-02-22 Children's Hospital Medical Center Siklooksijenaz önleyicileri olarak merkapto türevleri.

Also Published As

Publication number Publication date
EP1024696A4 (fr) 2004-07-14
AU753657B2 (en) 2002-10-24
JP2001520174A (ja) 2001-10-30
AU1361299A (en) 1999-05-10
WO1999020110A1 (fr) 1999-04-29
EP1024696A1 (fr) 2000-08-09

Similar Documents

Publication Publication Date Title
US6245797B1 (en) Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
US6362190B2 (en) Method for treating inflammatory diseases by administering a thrombin inhibitor
US6136804A (en) Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
AU753657B2 (en) Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease
KR20050043744A (ko) 시클로옥시게나제-2 억제제/히스톤 데아세틸라제 억제제복합제제
AU753079B2 (en) Combination of a selective NMDA NR2B antagonist and a COX-2 inhibitor
WO2001022962A1 (fr) Combinaison anti-hypercholesterolemique
US20020016342A1 (en) Combination therapy using COX-2 selective inhibitor and thromboxane inhibitor and compositions therefor
WO2003039542A1 (fr) Therapie combinee pour le traitement de la maladie d'alzheimer
US20020115689A1 (en) Combination therapy for treating neurodegenerative disease
WO1999045913A1 (fr) Therapie associee destinee au syndrome ischemique coronarien aigu ainsi qu'a des troubles connexes
WO2003094924A1 (fr) Therapie de combinaison destinee a traiter des maladies a mediation par cyclooxygenase-2 chez des malades presentant un risque d'accident cardiovasculaire thrombotique
US20060079579A1 (en) Combinations of valsartan with cox-2 inhibitors
US6440967B1 (en) Combination of a GABAA alpha 5 inverse agonist and COX-2 inhibitor, NSAID, estrogen or vitamin E
CA2327585A1 (fr) Utilisation d'un inhibiteur de cox-2 et d'un antagoniste du recepteur nk-1 dans le traitement de l'inflammation
US20040097573A1 (en) Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation
US20030035795A1 (en) Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor
AU715676B2 (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US20050215611A1 (en) Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events
HK1024872B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead